Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.31475
Abstract: This cross-sectional study evaluates the association of generic competition and changes in product coverage and cost-sharing by using Medicare data and estimated out-of-pocket costs for the oral specialty drug abiraterone. read more here.
Keywords: coverage; abiraterone; evaluation medicare; estimated pocket ... See more keywords
Biomarkers for predicting abiraterone treatment outcome and selecting alternative therapies in castration-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2582
Abstract: Approximately One-third of metastatic castration-resistant prostate cancer (mCRPC) patients exhibited primary abiraterone resistance. To identify alternative treatment for abiraterone non-responders, we performed drug discovery analyses using the L1000 database using differentially expressed genes identified in… read more here.
Keywords: cancer; alternative therapies; castration resistant; abiraterone ... See more keywords
Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03882-7
Abstract: Ipatasertib is a selective inhibitor of Akt, a frequently activated protein kinase in human cancers. The current study assessed the safety, tolerability, and pharmacokinetics of ipatasertib in Japanese patients with solid tumors. This was a… read more here.
Keywords: solid tumors; combination abiraterone; japanese patients; day ... See more keywords
Epoxidation is the preferred pathway of first-stage metabolism of abiraterone acetate in brown bullhead (Ameiurus nebulosus)
Sign Up to like & getrecommendations! Published in 2019 at "Environmental Science and Pollution Research"
DOI: 10.1007/s11356-019-06568-y
Abstract: Twenty juvenile individuals of brown bullhead (Ameiurus nebulosus), average weight 77 g, were fed by abiraterone acetate prodrug dissolved in olive oil via gastric probe. Dose applied was 3 mg/10 g fish weight. After feeding,… read more here.
Keywords: ameiurus nebulosus; bullhead ameiurus; abiraterone acetate; abiraterone ... See more keywords
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2017.03.007
Abstract: In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). Limited information exists regarding response to subsequent androgen signaling-directed therapies following abiraterone acetate plus… read more here.
Keywords: plus prednisone; abiraterone; abiraterone acetate; acetate plus ... See more keywords
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Sign Up to like & getrecommendations! Published in 2019 at "European urology"
DOI: 10.1016/j.eururo.2018.12.015
Abstract: BACKGROUND Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL). OBJECTIVE To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus enzalutamide. DESIGN, SETTING, AND PARTICIPANTS… read more here.
Keywords: fact; abiraterone; versus enzalutamide; quality life ... See more keywords
Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
Sign Up to like & getrecommendations! Published in 2019 at "European urology"
DOI: 10.1016/j.eururo.2019.01.026
Abstract: Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal events. We hypothesize that this… read more here.
Keywords: combined radium; radium 223; prostate cancer; higher risk ... See more keywords
Evaluation of dried blood spots as an alternative matrix for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in prostate cancer patients.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2020.113861
Abstract: Therapeutic drug monitoring (TDM) approaches may benefit patients treated with abiraterone acetate (AA) as drug efficacy is imprecise and important pharmacokinetic variability is known. Current methods based on the analysis of plasma present the disadvantage… read more here.
Keywords: analysis; therapeutic drug; abiraterone; drug monitoring ... See more keywords
Role of Silica Intrawall Microporosity on Abiraterone Acetate Solubilization and In Vivo Oral Absorption.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.1c00781
Abstract: SBA-15 mesoporous silica (MPS) has been widely used in oral drug delivery; however, it has not been utilized for solidifying lipid-based formulations, and the impact of their characteristic intrawall microporosity remains largely unexplored. Here, we… read more here.
Keywords: solubilization; solubilization vivo; vivo oral; microporosity ... See more keywords
PARP inhibitors synergize with abiraterone
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0060-9
Abstract: Poly(ADPribose) polymerase (PARP) inhibitors have been previously shown to improve the outcomes of patients with BRCAmutant prostate cancer. Now, data from a phase II study demonstrate that the PARP inhibitor olaparib, in combination with abiraterone,… read more here.
Keywords: parp inhibitors; abiraterone plus; synergize abiraterone; inhibitors synergize ... See more keywords
A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration‐resistant metastatic prostate cancer
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13532
Abstract: Decreased abiraterone exposure after introducing carbamazepine. read more here.
Keywords: abiraterone exposure; decrease abiraterone; clinically relevant; abiraterone ... See more keywords